StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30136% above fair value
$163.81−6.48 (-3.81%)

Close on Nov 20, 2026Market cap $10.47BP/E –Yield –

Repligen free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Repligen's free cash flow for the twelve months ending Sep 30, 2026 was $106.72M, down 3.0% year over year. For fiscal 2025 it was $93.90M, down 37.3% from the year before. Over ten years it grew 22.4% a year on average. The highest annual figure on record is $149.72M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$93.90M-37.3%
FY2024Dec 31, 2024$149.72M+92.7%
FY2023Dec 31, 2023$77.70M-10.9%
FY2022Dec 31, 2022$87.25M+68.0%
FY2021Dec 31, 2021$51.93M+29.3%
FY2020Dec 31, 2020$40.17M-17.5%
FY2019Dec 31, 2019$48.71M+120.1%
FY2018Dec 31, 2018$22.14M+84.5%
FY2017Dec 31, 2017$12.00M+275.4%
FY2016Dec 31, 2016$3.20M-74.3%
FY2015Dec 31, 2015$12.43M-2.9%
FY2014Dec 31, 2014$12.80M-39.9%
FY2013Dec 31, 2013$21.30M+686.6%
FY2011Mar 31, 2011$2.71M–
FY2010Mar 31, 2010-$3.05M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$38.15M-12.1%
Q2 FY2026Jun 30, 2026$27.43M+27.5%
Q1 FY2026Mar 31, 2026$23.59M+106.1%
Q4 FY2025Dec 31, 2025$17.55M-47.8%
Q3 FY2025Sep 30, 2025$43.40M+2.5%
Q2 FY2025Jun 30, 2025$21.51M-42.5%
Q1 FY2025Mar 31, 2025$11.44M-68.5%
Q4 FY2024Dec 31, 2024$33.64M+87.1%
Q3 FY2024Sep 30, 2024$42.34M+37.3%
Q2 FY2024Jun 30, 2024$37.38M+42.5%
Q1 FY2024Mar 31, 2024$36.36M+1274.7%
Q4 FY2023Dec 31, 2023$17.98M-56.6%
Q3 FY2023Sep 30, 2023$30.85M+4.4%
Q2 FY2023Jun 30, 2023$26.23M+28.9%
Q1 FY2023Mar 31, 2023$2.65M–
Q4 FY2022Dec 31, 2022$41.44M+136.8%
Q3 FY2022Sep 30, 2022$29.55M+154.9%
Q2 FY2022Jun 30, 2022$20.35M-3.8%
Q1 FY2022Mar 31, 2022-$4.09M-343.8%
Q4 FY2021Dec 31, 2021$17.50M+402.4%
Q3 FY2021Sep 30, 2021$11.59M-34.6%
Q2 FY2021Jun 30, 2021$21.16M+55.9%
Q1 FY2021Mar 31, 2021$1.68M-68.9%
Q4 FY2020Dec 31, 2020$3.48M-67.1%
Q3 FY2020Sep 30, 2020$17.71M+8.0%
Q2 FY2020Jun 30, 2020$13.57M-3.3%
Q1 FY2020Mar 31, 2020$5.40M-29.8%
Q4 FY2019Dec 31, 2019$10.58M+362.5%
Q3 FY2019Sep 30, 2019$16.40M-1.9%
Q2 FY2019Jun 30, 2019$14.03M+350.4%
Q1 FY2019Mar 31, 2019$7.70M+96150.0%
Q4 FY2018Dec 31, 2018$2.29M-83.0%
Q3 FY2018Sep 30, 2018$16.72M–
Q2 FY2018Jun 30, 2018$3.12M+117.4%
Q1 FY2018Mar 31, 2018$8.00K–
Q4 FY2017Dec 31, 2017$13.45M+1132.8%
Q3 FY2017Sep 30, 2017-$2.74M–
Q2 FY2017Jun 30, 2017$1.43M–
Q1 FY2017Mar 31, 2017-$148.00K–
Q4 FY2016Dec 31, 2016$1.09M–

More Repligen figures

See a number that looks wrong?